ppRB.sup.110 - nuclear phosphoprotein - the retinoblastoma susceptibility gene product
US5578701A · kind A · utility
1Cited by
1References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 8, 1994 |
| Grant date | Nov 26, 1996 |
| Priority date | — |
| Expiry date | Apr 8, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/828
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
This invention relates in general to a phosphoprotein product of the retinoblastoma susceptibility gene. In particular, this invention relates to a phosphoprotein ppRB.sup.110 primarily located in the cell nucleus which has a DNA binding activity. The invention also relates to the amino acid sequence of the phosphoprotein and to the specific purified anti-retinoblastoma phosphoprotein antibody. The invention further relates to a method of diagnosing retinoblastoma and other retinoblastoma gene involved cancers, treating such kind of cancers and regulating the oncogenicity of other genes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.